A. Gardin

发表

Tyrosine kinase receptors as attractive targets of cancer therapy.

Pierre Hubert, D. Aunis, A. Bennasroune, 2004, Critical reviews in oncology/hematology.

Inhibition by transmembrane peptides of chimeric insulin receptors

D. Aunis, A. Appert-Collin, A. Bennasroune, 2005, Cellular and Molecular Life Sciences CMLS.

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.

E. Legangneux, S. Neelakantham, Swati Dumitras, 2020, Clinical therapeutics.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics

G. Camenisch, M. Ufer, Felix Huth, 2017, European Journal of Clinical Pharmacology.

Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.

N. Gray, S. Lefebvre, Jianwei Che, 2013, ACS medicinal chemistry letters.

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

S. Neelakantham, C. Kolly, K. Shakeri-Nejad, 2021, Psychopharmacology.

Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism

K. Schroer, E. Legangneux, A. Meissner, 2018, Drug Metabolism and Disposition.

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights

E. Briard, A. Hofmann, C. Beerli, 2021, Multiple sclerosis journal - experimental, translational and clinical.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

E. Legangneux, T. Marbury, Zhenzhong Su, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

Transmembrane peptides as inhibitors of ErbB receptor signaling.

D. Aunis, A. Bennasroune, S. Dirrig‐Grosch, 2004, Molecular biology of the cell.

Dose‐dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship

B. Steinhoff, T. Mayer, F. Rosenow, 2015, Epilepsia.

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study .

E. Legangneux, S. Neelakantham, S. Kalluri, 2017, International journal of clinical pharmacology and therapeutics.

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

N. Gray, T. Sing, B. Nuesslein-Hildesheim, 2012, British journal of pharmacology.

Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.

E. Legangneux, A. Gardin, Donald R. Johns, 2013, British journal of clinical pharmacology.

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations

K. Umehara, A. Gardin, Handan He, 2019, Clinical pharmacology and therapeutics.

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects

G. Rossato, E. Legangneux, P. Pal, 2018, Clinical Pharmacokinetics.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety

B. Kiese, A. Gardin, K. Kucher, 2009, Drug Metabolism and Disposition.

Intestinal Lymphatic Transport Enhances the Post-Prandial Oral Bioavailability of a Novel Cannabinoid Receptor Agonist Via Avoidance of First-Pass Metabolism

Christopher J. H. Porter, David M. Shackleford, G. Edwards, 2009, Pharmaceutical Research.

Substitution of the insulin receptor transmembrane domain with that of glycophorin A inhibits insulin action

D. Aunis, C. Auzan, E. Clauser, 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

Pharmacokinetics of Licarbazepine in Healthy Volunteers: Single and Multiple Oral Doses and Effect of Food

A. Krebs-Brown, G. Greig, C. Souppart, 2008, Journal of clinical pharmacology.